THE BANK OF NEW YORK MELLON
101 Barclay Street
New York, New York 10286
June 4, 2015
Securities & Exchange Commission
450 Fifth Street, NW
Washington, DC 20549
Attn.: Document Control
||American Depositary Shares evidenced by Each (1) American Depositary Share representing Ten (10) deposited shares of|
||BiolineRX (Form F-6 File No. 333-175360)|
Ladies and Gentlemen:
Pursuant to Rule 424(b)(3) under the Securities Act of 1933,
as amended, on behalf of BNY Mellon, as Depositary for securities against which American Depositary Receipts are to be issued,
we attach a copy of the new prospectus (“Prospectus”) reflecting the change in ratio for BiolineRX.
As required by Rule 424(e), the upper right hand corner of
the Prospectus cover page has a reference to Rule 424(b)(3) and to the file number of the registration statement to which the Prospectus
Pursuant to Section III B of the General Instructions to the
Form F-6 Registration Statement, the Prospectus consists of the ADR certificate with revised ratio change for BiolineRX.
The Prospectus has been revised to reflect the new ratio of:
Each American Depositary Share Represents One (1) Deposited Share.
Please contact me with any questions or comments at 212 815-8162
The Bank of New York Mellon - ADR Division
cc: Paul Dudek, Esq. (Office of International Corporate Finance)